Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98
Tarsus Pharmaceuticals Inc TARS
$59.04
▼ -0.84%
($-0.50)
📅 Earnings This Week
Open
$58.85
Prev Close
$59.54
Day Range
$57.32 – $59.33
52W Range
$38.51 – $85.25
Market Cap
$2.54B
Beta
0.52
EPS (TTM)
$-1.13
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-16 |
| Shares Out. | 43,020,000 |
| Website | tarsusrx.com/ ↗ |
| Phone | 13025310855 |
| Employees | 370 |
| Revenue | $162.1M |
| Gross Profit | $152.7M |
| Net Income | -$7.0M |
| Free Cash Flow | -$31.5M |
| Total Assets | $581.1M |
| Total Liabilities | $232.2M |
| Equity | $349.0M |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals Inc is a publicly traded company under the ticker symbol TARS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)